Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2021; 9(29): 8846-8851
Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8846
Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report
Wen Li, Xiang He, Hui Liu, Jiong Zhu, Hui-Min Zhang
Wen Li, Xiang He, Jiong Zhu, Hui-Min Zhang, Department of Dermatology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
Hui Liu, Department of Oncology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
Author contributions: Li W contributed by collecting and assembling data; Li W and He X conceived, designed the research, analyzed and interpreted data; Zhang HM and He X funded the research; Li W and Liu H provided study materials or patients; All authors wrote the paper.
Supported by National Natural Science Foundation of China, No. 81974570.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Min Zhang, Director, Doctor, Department of Dermatology, Shuguang Hospital Affiliated to Shanghai University of TCM, No. 528 Zhangheng Road, Shanghai 201203, China. zhanghm@shutcm.edu.cn
Received: May 12, 2021
Peer-review started: May 12, 2021
First decision: June 15, 2021
Revised: June 18, 2021
Accepted: August 18, 2021
Article in press: August 18, 2021
Published online: October 16, 2021
Processing time: 155 Days and 18.8 Hours
Core Tip

Core Tip: To the best of our knowledge, this is the first case reported in a patient with epidermal growth factor receptor T790M mutation in non-small cell lung cancer. Cabozantinib combined with erlotinib had clinically meaningful effectiveness, with additional toxicity that was generally manageable.